Samsung / GSK — Rockville
Samsung Biologics completed its acquisition of GSK's Rockville manufacturing facility on March 31, 2026 after a $280 million agreement announced in December 2025. The transaction changed ownership, but that does not by itself establish a change in every regulated legal entity or authorization at the site.
Facility identity
Address: 9911 Belward Campus Drive, Rockville, MD 20850
Acquired entity: Human Genome Sciences, Inc.
Buyer: Samsung Biologics America
Agreement announced: December 22, 2025
Acquisition completed: March 31, 2026
Agreement value: $280 million
What the public record shows
Samsung Biologics' December 2025 announcement says its U.S. subsidiary agreed to acquire 100% of Human Genome Sciences from GSK, including the Rockville manufacturing site. Samsung then announced completion of the acquisition on March 31, 2026. Historical SEC transaction documents independently identify Human Genome Sciences at 9911 Belward Campus Drive.
The evidence is useful because it separates corporate ownership from program-specific regulatory identity. A regulator record that retains a predecessor or subsidiary name after closing would not, by itself, prove a missing successor authorization.
Evidence boundary
Sentinel treats this as an entity-continuity question, not a permit-gap conclusion. The post-closing operator, regulated legal entity and authorization holder must be established program by program before declaring a successor-record problem.
Sources
Samsung Biologics — December 22, 2025 acquisition agreement
Samsung Biologics — March 31, 2026 acquisition completion
U.S. SEC — Human Genome Sciences site identity